Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» GLP-1 agonist
GLP-1 agonist
Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound
BioSpace
Mon, 12/11/23 - 10:58 pm
Eli Lilly
weight loss
Zepbound
GLP-1 agonist
ADC and GLP-1 Rocket Ride Continues as 2023 Comes to Close
BioSpace
Sun, 12/3/23 - 09:34 pm
antibody-drug conjugate
GLP-1 agonist
Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News
BioSpace
Fri, 12/1/23 - 09:46 am
Altimmune
clinical trials
obesity
GLP-1 agonist
pemvidutide
Novo to expand French plant in GLP-1 production push
BioPharma Dive
Tue, 11/28/23 - 10:30 am
Novo Nordisk
GLP-1 agonist
France
drug manufacturing
GLP-1 Agonists, Like Ozempic and Wegovy, Have Risk of Gut Issues: Study
BioSpace
Thu, 10/5/23 - 09:07 pm
Novo Nordisk
Ozempic
Wegovy
GLP-1 agonist
JAMA
Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan
Fierce Pharma
Mon, 09/11/23 - 12:26 pm
Novo Nordisk
Eli Lilly
GLP-1 agonist
obesity
GLP-1 Drugs Show Promise in Alcohol, Opioid Use Disorders
BioSpace
Thu, 08/3/23 - 10:05 am
GLP-1 agonist
alcohol-use disorder
opioid use disorder
AstraZeneca drops another GLP-1 after phase 1 data bust market-beating diabetes hopes
Fierce Biotech
Tue, 06/20/23 - 10:15 am
AstraZeneca
GLP-1 agonist
AZD0186
type 2 diabetes
BIO: Can GLP-1s help you quit smoking or drinking? Lilly is looking into it—cautiously
Fierce Biotech
Fri, 06/9/23 - 11:47 am
BIO 2023
Eli Lilly
GLP-1 agonist
smoking cessation
alcohol-use disorder
Lilly steps up its oral obesity push
EP Vantage
Thu, 05/25/23 - 08:45 pm
Eli Lilly
obesity
GLP-1 agonist
orforglipron
Study: Type 2 Diabetes Treatments May Be More Effective When Combined
BioSpace
Sun, 08/30/20 - 11:27 pm
diabetes
type 2 diabetes
FGF21
GLP-1 agonist
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
CP Wire
Tue, 10/29/19 - 01:55 pm
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
Tue, 10/29/19 - 01:54 pm
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
Tue, 07/24/18 - 10:32 am
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Fierce Pharma
Wed, 05/2/18 - 07:24 pm
Novo Nordisk
GLP-1 agonist
diabetes
Ozempic
drug launches
GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out
Fierce Biotech
Sat, 04/28/18 - 12:15 pm
Sanofi
clinical trials
GLP-1 agonist
SAR425899
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
Market Realist
Mon, 03/5/18 - 09:24 am
Novo Nordisk
GLP-1 agonist
diabetes
Victoza
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst
Fierce Pharma
Tue, 08/1/17 - 10:48 pm
GSK
GLP-1 agonist
Tanzeum
Sanofi
AstraZeneca
New Novo Nordisk Strategy Drops Oral Insulin, Expands Oral GLP-1
Seeking Alpha
Sun, 10/30/16 - 11:14 am
Novo Nordisk
diabetes
oral insulin
insulin
GLP-1 agonist
R&D
Sanofi Should Be Thinking Longer Duration In GLP-1s
Seeking Alpha
Tue, 08/2/16 - 09:09 am
Sanofi
GLP-1 agonist
Adlyxin
Pages
« first
‹ previous
1
2
3
4
next ›
last »